SAB Biotherapeutics (NASDAQ:SABS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of SAB Biotherapeutics (NASDAQ:SABS) from a sell rating to a strong sell rating in a research report released on Sunday morning.

A number of other research analysts also recently commented on SABS. Barclays began coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 price objective on the stock. Chardan Capital upped their price target on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Leerink Partners raised their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Citigroup assumed coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Wednesday, July 8th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $3.85 on Friday. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $3.67 and a 200-day simple moving average of $3.83. The stock has a market cap of $294.37 million, a P/E ratio of -1.82 and a beta of 0.53. SAB Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Equities analysts expect that SAB Biotherapeutics will post -1.19 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $32,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at $30,000. Virtu Financial LLC purchased a new stake in SAB Biotherapeutics in the 3rd quarter valued at $40,000. RA Capital Management L.P. purchased a new stake in SAB Biotherapeutics in the 3rd quarter valued at $8,847,000. Finally, Vivo Capital LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter worth $22,954,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.